Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038857 · ClinicalTrials.gov registry record · Phase 2
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00038857: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00038857 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038857, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies. The primary objectives of the study are to evaluate the recipient obtaining donor derived neutrophil engraftment and the incidence of acute graft versus host disease \[GvHD\] (grade III-IV). Secondary objectives include assessments of recipient having donor derived platelet engraftment, incidence of graft failure and chronic GvHD, overall and disease free survival, clinical safety and device performance of the CliniMACS CD34 selection device.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Thiotepa
- DRUG Rabbit ATG
- PROCEDURE Megadose of CD34 Selected Progenitor Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2001-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038857
The ClinicalTrials.gov registry entry for NCT00038857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00038857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038857 about?
NCT00038857 is a clinical study titled "Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases". Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies. The primary objectives of the study are to evaluate the recipient obtaining donor derived neutrophil engraftment and the inci...
What is the current status of trial NCT00038857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2001-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00038857?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Thiotepa (DRUG), Rabbit ATG (DRUG), Megadose of CD34 Selected Progenitor Cells (PROCEDURE).
Who is sponsoring clinical trial NCT00038857?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.